The activators and components of the MAPK pathway—Raf, RAS, BRAF, MEK, and ERK—are frequently mutated in colon, melanoma, ovarian, thyroid, colorectal, and non-small cell lung cancers [33]. Here, BRAF is linked to non-small cell lung carcinoma.